CURN and KNRS Related Headlines
Go Back- Curatis Increases Revenue Growth Guidance for 2026
- Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
CURN and KNRS Related Press Releases
Go Back- Curatis Increases Revenue Growth Guidance for 2026
- Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
